Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

03-0197-00 SMC™ Human SARS-CoV-2 S1 IgA Kit

Assay mechanism includes proprietary elution and digital molecular counting steps that enable the SMC™ SARS-CoV-2 S1 IgA kit to detect antigen specific IgA in human serum and plasma at much lower levels compared to traditional immunoassays.

SMC™ Human SARS-CoV-2 S1 IgA Kit MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.
Key Applications: Single Molecule Counting (SMC®) Research Category: Inflammation & Immunology, Immune Response, Infectious Diseases, Isotyping Research Sub-Category: Inflammatory Disease, Immune Response, Virology, Infectious Diseases - Viral, Immunoglobulins & Immunology
View Products on Sigmaaldrich.com
03-0197-00
96 well assay  
Purchase on Sigma-Aldrich

Overview

Replacement Information

Key Spec Table

Key Applications
Single Molecule Counting (SMC®)
Description
Catalogue Number03-0197-00
Trade Name
  • SMC®
DescriptionSMC™ Human SARS-CoV-2 S1 IgA Kit
OverviewThe Single Molecule Counting (SMC™) Human SARS-CoV-2 S1 IgA kit uses a fluorescent sandwich immunoassay technique to measure SARS-CoV-2 S1 IgA in Human EDTA Plasma and Serum samples. A Human SARS-CoV-2 S1 capture protein has been pre-coated onto paramagnetic microparticles (beads). The user pipettes beads and samples into uncoated microplate wells. During incubation, the SARS-CoV-2 S1 IgA present in the sample binds to the capture protein on the coated beads. Unbound molecules are washed away during the subsequent wash steps. Fluor-labeled detection antibody is added to each well and incubated. This detection antibody recognizes and binds to IgA antibodies against SARS-CoV-2 S1 that have been captured onto the beads, thus completing the immunosandwich. Elution buffer is then added and incubated. The elution buffer dissociates the bound protein sandwich from the beads surface releasing the labeled antibodies. These antibodies are separated during transfer to a final microplate. The plate is loaded into the SMCxPRO™ System where the labeled molecules are detected and counted. The number of fluor-labeled detection antibodies counted is directly proportional to the amount of SARS-CoV-2 S1 IgA present in the sample when captured. The amount of SARS-CoV-2 S1 IgA in unknown samples is qualitatively assessed in raw signal to determine COVID-19 infection when compared against known negative samples.
Background InformationImmunoassay-based serology techniques play key roles in many SARS-CoV-2 research programs due to their ability to identify and characterize sample of infected individuals long after initial exposure. However, many traditional assay platforms, due to limitations in sensitivity and resolution, may not be truly optimal for use in situations where low-level characterization and stratification of SARS-CoV-2 antibody responses are essential, such as population studies, temporal infection timecourse experiments, and evaluating vaccine efficacy.
The Single Molecule Counting (SMC™) ultrasensitive immunoassay platform has been harnessed toward the development of new products for detecting SARS-CoV-2 mediated antibody response. The new SMC™ SARS-CoV-2 S1 IgA kit can be used by researchers to accurately understand the extent of SARS-CoV-2 infection in society, thoroughly profile immune response after natural or vaccine-induced exposure, demonstrate persistence of long-term antibody post-infection, and understand the extent of immune heterogeneity among individuals and subpopulations.
References
Product Information
Components
  • Assay Buffer
  • SARS-CoV-2 S1 IgA Beads
  • Standard Diluent
  • SARS-CoV-2 S1 IgA Detection Antibody
  • 10X Wash Buffer
  • Buffer D
  • Elution Buffer B
Precision, %
  • The assay variation of the SMC™ Human SARS-CoV-2 S1 IgA Immunoassay
    kit were studied using fourteen plasma samples, run in triplicate in three
    separate runs.
  • Mean intra-assay variation for all samples was < 9%.
  • Mean inter-assay variation for all samples was < 15%.
Applications
ApplicationAssay mechanism includes proprietary elution and digital molecular counting steps that enable the SMC™ SARS-CoV-2 S1 IgA kit to detect antigen specific IgA in human serum and plasma at much lower levels compared to traditional immunoassays.
Key Applications
  • Single Molecule Counting (SMC®)
Application NotesThis new kit has the following features:
• For use with the state of the art SMCxPRO™ Ultrasensitive Immunoassay System
• Qualitative assay; no standard curve
• For Research Use Only. Not For Use In Diagnostic Procedures
• Detects SARS-CoV-2 S1 specific IgA antibody as early as 3 days after PCR positive result
• Requires as little as 2μL of human serum and plasma sample (1:50 recommended dilution)
• Fast assay protocol (one hour capture, 30 minute detection steps)
Biological Information
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Usage Statement
  • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Storage and Shipping Information
Packaging Information
Material Size96 well assay
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Catalogue Number GTIN
03-0197-00 04065265648523